JPM vs MATH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
MATH presents a stark contrast between strong deterministic health scores and deteriorating business fundamentals. While the Piotroski F-Score of 7/9 indicates strong financial health and the stock trades below both its Graham Number ($1.86) and Intrinsic Value ($1.26), these value signals are offset by a severe -39% YoY revenue decline. The company maintains a debt-free balance sheet, but a critical liquidity gap is evident in the Quick Ratio of 0.09. Overall, the stock is fundamentally undervalued but lacks a growth catalyst and faces significant operational headwinds.
Compare Another Pair
Related Comparisons
JPM vs MATH: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Metalpha Technology Holding Limited (MATH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.